Karyopharm Therapeutics (NASDAQ: KPTI) reported Q4 EPS of ($0.79), $0.14 worse than the analyst estimate of ($0.65).

Guidance:

Based on current operating plans, Karyopharm expects that its existing cash and cash equivalents will fund its research and development programs and operations into 2018, including moving registration-directed clinical studies to their next data inflection points. Karyopharm expects to end 2015 with greater than $200 million in cash, cash equivalents and investments.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.